 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday...

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Renalytix appoints Howard Doran as Chief Business Officer

Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales EffortLONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE...

Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

For the last three days, A.I.dvisor has detected that RNLX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Renalytix (RNLX, $3.02) Aroon Indicator entered a Downtrend on August 28, 2023.

Renalytix Plc (NASDAQ:RNLX  Get Free Report) shares were up 7.6% during mid-day trading on Friday . The stock traded as high as $3.66 and last traded at $3.54. Approximately 182,076 shares changed hands during trading, a decline of 45% from the average daily volume of 328,666 shares. The ...

Renalytix (NASDAQ:RNLX) Shares Up 7.6%

Renalytix (NASDAQ:RNLX Get Free Report) and Cue Health (NASDAQ:HLTH Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, ...

Head to Head Review: Renalytix (NASDAQ:RNLX) & Cue Health (NASDAQ:HLTH)

Commercial availability of kidneyintelX.dkd expanded to an estimated4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally LONDON and SALT ...

Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Renalytix (NASDAQ:RNLX Get Free Report) and HH&L Acquisition (NYSE:HHLA Get Free Report) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, ...

Head to Head Survey: Renalytix (NASDAQ:RNLX) versus HH&L Acquisition (NYSE:HHLA)

This is a signal that RNLX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Renalytix (RNLX, $3.19) RSI Indicator left the overbought zone on July 07, 2023

12 Months KidneyIntelX in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023 (...

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

Watchers	694
52-Wk Low	$1.05
52-Wk High	$4.04

Market Cap	$103.57M
Volume (M)	1,969.00
52-Wk High	$4.04
52-Wk Low	$1.05

RNLX Renalytix AI Plc - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals